论文部分内容阅读
Hamsten 等人测量62例急性心肌梗塞(AMI)的年轻幸存者的抗心脂抗体(aCL),发现有13例 aCL 增高,且其中8例在定期观察中发生心血管意外。故建议将 aCL 作为年轻 AMI 患者再次发生心血管意外的高度危险标志。本文试图发现对 AMI 患者能否将抗脑磷脂抗体(aCEPHA)或 aCL 抗体作为判断死亡率、再梗塞及非出血性中风的一种独立的危险标志。病人和方法 AMI 病人597例,男女之比为3.3:1,平均年龄61.6岁。平均观察时间为1172天。对照组为158名健康供血者及老年白内障门诊病人,平均年龄47.3岁。在梗塞后平均27.6天检测血中的 aCEPHA 及 aCL。
Hamsten et al. Measured anti-lipoidal antibodies (aCL) in 62 survivors of acute myocardial infarction (AMI) and found an increased aCL in 13 of them, and 8 of these occurred during regular observation of cardiovascular events. It is therefore recommended that aCL be used as a high risk of cardiovascular reoccurrence in young AMI patients. This article attempts to find out whether anti-cephalin antibody (aCEPHA) or aCL antibody can be an independent risk marker for assessing mortality, reinfarction and non-hemorrhagic stroke in AMI patients. Patients and Methods 597 AMI patients, male to female ratio of 3.3: 1, the average age of 61.6 years old. The average observation time was 1172 days. The control group was 158 healthy donors and elderly cataract patients, with an average age of 47.3 years. ACEPHA and aCL in blood were detected on average 27.6 days after infarction.